Literature DB >> 31626886

Risk of second primary cutaneous and noncutaneous melanoma after cutaneous melanoma diagnosis: A population-based study.

Kourosh Beroukhim1, Aunna Pourang2, Daniel B Eisen3.   

Abstract

BACKGROUND: While cutaneous melanomas (CM) account for greater than 90% of all melanomas, noncutaneous melanomas (NCM) are more aggressive and associated with worse outcomes. The shared progenitor cell type among CM and NCM suggests that patients with a history of CM may be at higher risk for subsequent NCM.
OBJECTIVE: To determine whether patients with a history of CM demonstrate an increased risk of second primary cutaneous, ocular, oral, or vaginal/exocervical melanoma compared with the general population.
METHODS: This was a population-based retrospective cohort study using the Surveillance, Epidemiology, and End Results database. We calculated standardized incidence ratios (SIRs) and excess absolute risks of second primary cutaneous, ocular, oral, and vaginal/exocervical melanoma in patients with a history of CM.
RESULTS: Patients with prior CM (n = 169,841) were more likely than the general population to develop a second primary CM (SIR, 8.17; 95% confidence interval [CI], 8.01-8.33), ocular melanoma (SIR, 1.99; 95% CI, 1.54-2.53), oral melanoma (SIR, 6.87; 95% CI, 2.23-16.04), and vaginal/exocervical melanoma (SIR, 10.17; 95% CI, 4.65-19.30). LIMITATIONS: This study is limited by possible under-reporting of CM in cancer registries.
CONCLUSION: In caring for patients with a history of CM, physicians should be vigilant not only about risk of recurrence but also about second primary CM and NCM.
Copyright © 2019 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Epidemiology; Surveillance; and End Results program; cutaneous melanoma; melanoma; noncutaneous melanoma; screening; second primary melanoma

Year:  2019        PMID: 31626886     DOI: 10.1016/j.jaad.2019.10.024

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  5 in total

Review 1.  Follow-up of primary melanoma patients with high risk of recurrence: recommendations based on evidence and consensus.

Authors:  Begoña Campos-Balea; Ovidio Fernández-Calvo; Roberto García-Figueiras; Carlos Neira; Carmen Peña-Penabad; Carmela Rodríguez-López; Rocío Vílchez-Simo; María Quindós-Varela
Journal:  Clin Transl Oncol       Date:  2022-03-28       Impact factor: 3.340

2.  Incidence of Second Primary Melanoma in Cutaneous Melanoma Survivors.

Authors:  Alyssa A Wiener; Jessica R Schumacher; Jennifer M Racz; Sharon M Weber; Yaohui G Xu; Heather B Neuman
Journal:  Ann Surg Oncol       Date:  2022-05-03       Impact factor: 4.339

3.  Assessment of Trends in Second Primary Cancers in Patients With Metastatic Melanoma From 2005 to 2016.

Authors:  Weiye Deng; Yifan Wang; Xiangyu Liu; Jieqiong Liu; Liang Wang; Zhaogang Yang; Mingming Yang; Yi An; Chad Tang; Nina N Sanford; Betty Y S Kim; Wen Jiang
Journal:  JAMA Netw Open       Date:  2020-12-01

4.  Nation-Wide Trends in Incidence-Based Mortality of Patients with Ocular Melanoma in USA: 2000 to 2018.

Authors:  Srijan Valasapalli; Achuta Kumar Guddati
Journal:  Int J Gen Med       Date:  2021-08-05

Review 5.  Magnetic nanoparticles in theranostics of malignant melanoma.

Authors:  Maxim Shevtsov; Susanne Kaesler; Christian Posch; Gabriele Multhoff; Tilo Biedermann
Journal:  EJNMMI Res       Date:  2021-12-14       Impact factor: 3.138

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.